SecBot SecBot
Biotech Drug Report Generated Oct 31, 2026

Cerezyme

SNY·Sanofi
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and commercialized since 1994. The latest label expansion (Type 3 Gaucher) was approved by the FDA in January 2026.
Why 3/10
Cerezyme is already approved and commercialized with no pending regulatory decision. The most recent hard catalyst was the FDA label expansion in January 2026, which has already occurred. No PDUFA date, pivotal readout, or Advisory Committee is scheduled in the next 12 months, capping the impact score at 5. The drug represents roughly 0.4% of Sanofi's total revenue, further limiting any single-drug impact on the stock.
Actionable Insight NEUTRAL

The next catalyst for Cerezyme was the FDA label expansion in January 2026, which has already occurred. No new PDUFA or pivotal readout is scheduled for this mature product. Watch for biosimilar competition (Abcertin completed Phase 1 in July 2025) and quarterly sales trends in Sanofi's rare disease reporting, but neither is a binary event for the stock.

Price Chart

Loading chart...

Executive Summary

Cerezyme (imiglucerase) is Sanofi's mature enzyme replacement therapy for Gaucher disease, originally approved in 1994. In January 2026, the FDA expanded its label to include non-CNS symptoms of Type 3 Gaucher disease and pediatric patients under 2, making it the first approved therapy for that indication. The drug generated EUR 171 million in FY2025 sales (broadly stable, +2.9%), representing roughly 0.4% of Sanofi's total revenue. With no upcoming binary catalysts and biosimilar competition emerging (Abcertin Phase 1 completed July 2025), Cerezyme is a stable but low-growth legacy product within Sanofi's diversified portfolio.

How It Works

Cerezyme is an enzyme replacement therapy for Gaucher disease, a rare genetic disorder where the body cannot produce enough of an enzyme called glucocerebrosidase. Without this enzyme, fatty substances build up in cells, causing enlarged organs, bone problems, and blood disorders. Cerezyme is a manufactured version of the missing enzyme, given as an intravenous infusion every two weeks, to break down the fatty buildup and manage symptoms.

Trial Status

Cerezyme has been FDA-approved since 1994 for Type 1 Gaucher disease. In January 2026, the FDA approved a supplemental BLA expanding the indication to include non-CNS manifestations of Type 3 Gaucher disease in adults and pediatric patients, including those under 2 years old. The expansion was supported by real-world evidence from the International Collaborative Gaucher Group Registry with data from over 1,000 Type 1 and over 100 Type 3 patients.

The Two-Sided Case

▲ Bull Case3
The FDA expanded Cerezyme's label in January 2026 to include non-CNS symptoms of Type 3 Gaucher disease and pediatric patients under 2 years old, making it the first and only FDA-approved therapy for Type 3 Gaucher, which could support patient growth.
Cerezyme has over 30 years of real-world use and is the #1 prescribed enzyme replacement therapy for Gaucher disease Type 1 in the U.S., giving it strong brand recognition and physician familiarity.
Sanofi's Q3 2026 results showed double-digit growth with rare disease medicines contributing to improved product mix, and the company raised its full-year guidance, reflecting overall business strength.
▼ Bear Case4
Biosimilar competition is emerging: Abcertin, a biosimilar candidate for imiglucerase, met equivalence criteria in a Phase 1 study in July 2025, which could pressure Cerezyme's pricing and market share over time.
Cerezyme faces entrenched competition from other enzyme replacement therapies (Takeda's VPRIV, Pfizer's Elelyso) and oral substrate-reduction therapies (Cerdelga, Zavesca), limiting volume and pricing expansion.
Cerezyme sales were broadly stable at EUR 171 million in FY2025 (+2.9%), with price partly offsetting patient growth, indicating a mature product with limited growth trajectory.
The drug is a very small part of Sanofi's overall business (roughly 0.4% of EUR 43.6 billion in 2025 revenue), so even major changes in Cerezyme's performance would have negligible impact on Sanofi's stock.

Upcoming Catalysts

  • No upcoming PDUFA dates, pivotal readouts, or Advisory Committee meetings are scheduled for Cerezyme in the next 12 months.
  • Potential biosimilar entry: Abcertin (imiglucerase biosimilar) completed a Phase 1 study in July 2025, and further development could eventually lead to a biosimilar filing.
  • Quarterly sales trends in Sanofi's rare disease franchise reporting may provide incremental commercial updates.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Sanofi 6-K SNY ·Originating report

Sources · 10

Hover a chip for the title
1 gaucherdiseasenews.com2 sanofi.com3 accessdata.fda.gov4 gaucherdiseasenews.com5 sanofi.com6 accessdata.fda.gov7 products.sanofi.us8 pharmacytimes.com9 statista.com10 drugpatentwatch.com